Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with nonalcoholic steatohepatitis

Non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease (NAFLD), represents a large and growing public health concern that is increasingly contributing to the rising prevalence of cirrhosis and hepatocellular carcinoma globally[1,2]. Currently, there is no approved drug for NASH, which is projected to be the leading indication for liver transplantation in the next decade[3]. The pathogenesis of NASH is complex, and it is hypothesized that toxic lipid species or intermediates may inflict hepatocyte injury[4].

Source: Journal of Hepatology - December 7, 2018 Category: Gastroenterology Authors: Mary E. Rinella, James F. Trotter, Manal F. Abdelmalek, Angelo H. Paredes, Margery A. Connelly, Mark J. Jaros, Lei Ling, Stephen J. Rossi, Alex M. DePaoli, Stephen A. Harrison Source Type: research